Futura Medical PLC on Monday said that it has extended its exclusive licensing agreement with Cooper Consumer Health Group, a European self-care organisation, to January 2029.
The Guildford, Surrey-based pharmaceutical company has extended its deal for the rights to commercialise Eroxon, a topical, gel-based erectile dysfunction treatment, throughout the EU, UK, and Switzerland.
The extension builds on an initial agreement signed in May 2022 for the rights to commercialise Eroxon in these territories for an initial five-year period. The terms of the agreement are otherwise unchanged.
‘The award-winning launch of Eroxon was a key milestone in our partnership with Cooper and the success of our collaboration makes this extension an easy decision for both parties. We are committed to providing treatment to those suffering from ED and as such we continue the commercial roll-out of Eroxon across the world,’ said Chief Executive Officer James Barder.
Futura Medical shares were trading 0.6% higher at 34.19 pence each in London on Monday morning.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
